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Purpose: The aims of this study were to assess the
quality of responses produced by drug information
centers (DICs) in Scandinavia, and to study the
association between time consumption processing
queries and the quality of the responses.
Methods: We posed six identical drug-related queries
to seven DICs in Scandinavia, and the time consumption
required for processing them was estimated. Clinical
pharmacologists (internal experts) and general practi-
tioners (external experts) reviewed responses individu-
ally. We used mixed model linear regression analyses to
study the associations between time consumption on one
hand and the summarized quality scores and the overall
impression of the responses on the other hand.
Findings: Both expert groups generally assessed the
quality of the responses as “satisfactory” to “good.” A
few responses were criticized for being poorly synthesized
and less relevant, of which none were quality-assured
using co-signatures. For external experts, an increase in
time consumption was statistically signiﬁcantly associated
with a decrease in common quality score (change in1738score, –0.20 per hour of work; 95% CI, –0.33 to –0.06;
P ¼ 0.004), and overall impression (change in score, –
0.05 per hour of work; 95% CI, –0.08 to –0.01; P ¼
0.005). No such associations were found for the internal
experts’ assessment.
Implications: To our knowledge, this is the ﬁrst
study of the association between time consumption
and quality of responses to drug-related queries in
DICs. The quality of responses were in general good, but
time consumption and quality were only weakly asso-
ciated in this setting. (Clin Ther. 2016;38:1738–1749)
& 2016 The Authors. Published by Elsevier HS Journals,
Inc.
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There are no established accepted methods or criteria
for measuring the quality of drug information centers’
(DICs’) responses to queries.1 From the DICs’ points
of view, relevant quality assurance may include
properly trained staff members, standardized
working procedures, documentation of the working
process,2 and the use of co-signature by another staff
member.3 Most studies assessing the quality of drug
information services have been designed as user
satisfaction surveys, aiming to address health care
professionals’ evaluations of the responses.4–7 Such
surveys have been criticized as lacking objectivity8,9
and as being biased by evaluation of one’s own center
and not including users not responding.9 Some user
surveys have been focusing on the impact of these
services on patient care, assessed by health care
professionals.4–6,10–12 These methods have retrospec-
tive approaches, and the lack of controls to which the
actual outcomes could be compared has been
criticized.9 In addition, many factors other than the
DIC’s response can affect patient outcome.13
Scandinavian DICs have also published results from
users’ surveys, and the users have generally been very
satisﬁed with the services.4–6,14
Regardless of outcome measures, such surveys do
not indicate where the strengths and weaknesses of
DICs’ responses lie.2 In order to ensure high quality of
written responses from DICs, another proposed
method of assessment is to use an external
committee to review them.9,13 Several studies have
included such external reviews.8,15,16 Yet another way
of measuring the quality of responses from DICs has
been to pose the same query to several DICs at the
same time, comparing the responses given from differ-
ent services to each other and/or to a “control
response” giving the correct answer.15–19
Previous studies aiming to compare responses from
different DICs to identical queries have generally
revealed unsatisfactory results.15,17–19 Halbert et al19
posed the same telephone query to 90 different US
DICs in 1977. Ten centers were not able to identify
the drug in question, and 22 centers provided
information that was judged to be less than
adequate. Gallo et al15 posed identical queries to 20
hospital-based US DICs. A panel of ﬁve clinical
pharmacists assessed the directness, applicability, ac-
curacy, and completeness of the answers. Only nine
DICs provided an answer. The highest possible scoreJuly 2016was 100, and the responses’ scores ranged from 23 to
84, with a median of 62.
In 1990, Beaird et al18 randomly selected 59 of 154
DICs in the United States. They performed a telephone
request requiring the identiﬁcation of didanosine. If
the center was able to identify the drug, the staff
member was presented with a patient case with
symptoms of acute pancreatitis. Of the 56 centers
that were successfully contacted, only 16 identiﬁed the
drug as didanosine, and 4 recognized the clinical
symptoms of pancreatitis and associated it with the
use of didanosine. Calis et al17 evaluated responses
from US DICs responding to four drug-related
queries. Of the 79 centers that responded to all four
queries, none provided a correct overall response to
all, 13 had three overall correct responses, 42 had two
overall correct responses, 21 had one correct overall
response; 3 centers failed to answer any of the queries
correctly.
Better results were reported from two literature
search services in Australia serving general practi-
tioners (GPs). The services focused on answering
queries requiring thorough searching for evidence-
based documentation. Both services answered the
same 14 queries asked during the study period. One
person with experience in evidence-based medicine
rated the concordance between the reports. There
were substantial intersite differences in the evidence
sections of four of the reports, and minor dif-
ferences in another four. There were, however, no
substantial differences in the overall conclusions of the
reports.16
The Scandinavian DICs provide written responses to
almost all drug-related queries posed to the centers.
The centers are quite similar in structure and types of
queries, and have recently been studied in terms of time
consumption when responding to drug queries.20 That
study revealed that time spent by staff members
processing queries (in the present article designated
time consumption) varied largely both between queries
and between DICs. The quality of written responses
from these centers has not previously been compared.
One aim of this study was to assess the quality of
responses processed by Scandinavian DICs using both
internal experts (clinical pharmacologists) and exter-
nal experts (GPs). Another aim was to investigate
whether there was an association between time con-
sumed when processing the responses and their
quality.1739
Clinical TherapeuticsMATERIALS AND METHODS
All regional Scandinavian DICs (n¼ 11) were invited to
participate in the study. These DICs are governmentally
funded and afﬁliated with clinical pharmacology units
at university hospitals in their respective geographic
regions. The centers are manned by pharmacists and
clinical pharmacologists, and the centers’ aim is to
contribute to the rational use of drugs. One of the
main activities is to respond to health care professio-
nals’ drug-related queries. Typically, enquirers are
physicians posing patient-speciﬁc queries, requiring the
staff members to search for evidence, read and interpret
the scientiﬁc literature on the topic, and produce a
verbal and/or written response to the query. Motives for
applying for such information may be the need for
evidence-based information and decision support, and
the lack of time or skills to search the literature.6
Seven DICs chose to participate in the study.
During the 8-week study period (January–March
2013), the staff members reported the estimated time
consumption per response to all queries. The time
consumed per query included time needed to search
for, read, and interpret the literature; writing a
response; quality assurance by co-signature or discus-
sions with a colleague and all administrative tasks (eg,
indexing the query and response in a database); and
communication with the enquirer. The study was
reported to Norwegian Social Science Data Services
in accordance with national legislation.
Members of the project group delineated six ﬁcti-
tious study queries (Table I), all presented in the
Norwegian, Swedish, and Danish languages. During
the study period, GPs familiar with each center
simultaneously posed these study queries by e-mail
to all centers. We chose to pose a total of six queries,
as we did not want to give a large amount of extra
work to the centers. Staff members at the participating
centers were, for ethical reasons, informed about the
study, but were blinded in terms of how many and
which queries were study queries and how they were
going to be assessed. By posing the same study queries
to all centers, we were able to compare the responses
processed by the different centers.
Staff members at all seven centers produced re-
sponses to each of the six queries, and the GPs
received written responses by e-mail. The 42 responses
were distributed to the project leader (L.A.R.), who
anonymized the responses for staff members and
centers and distributed them to seven internal experts1740and six external experts who were recruited via the
leaders of the centers and who were familiar with the
services, for the assessment of quality. For the four
centers in Norway, this meant that the experts
reviewing them would be completely blinded by which
center had produced which answer. For the other
three centers, it was not possible to anonymize them
completely, as only one center in Sweden participated,
giving their answers in Swedish, and the two Danish
centers had very different styles, one of them giving
the main answer in English, the other one in Danish.
All 13 experts individually assessed the quality of
the responses, using a survey form with detailed
quality criteria. We developed the survey based on
our knowledge and experience from the DICs query-
answer service. The speciﬁc quality criteria are given
in Table II. Most criteria were scored on a ﬁve-point
scale (“in a very small degree” to “to a very large
degree”). In retrospect, all responses were converted
to numbers 0 ¼ poorest quality to 4 ¼ best quality.
Statistical Analysis
We performed mixed-model linear regression anal-
yses with total time as the independent variable, and
the common quality score, external experts’ sum
score, internal experts’ sum score (Table II), and
overall impression of the response, respectively, as
dependent variables. These analyses included crossed
random effects of centers, queries, and individual
experts. A statistical interaction between internal/
external experts and total time consumption was
included when relevant. These analyses used
restricted maximum likelihood estimation. We
performed the analyses with and without the
inclusion of the center with the highest mean time of
consumption, and with and without controlling for
the staff members’ experience (o2 or Z2 years).
To quantify the extent of agreement among ex-
perts, we used the Kendall’s coefﬁcient of concordance
(W) and Gwet’s agreement coefﬁcient with ﬁrst-order
chance correction (AC1). Kendall’s W was chosen
because we present ordinal variables assessed by
multiple experts.21 It quantiﬁes the extent of
agreement with respect to an expert’s ranking of
subjects,22 in this case, responses. It becomes,
however, increasingly difﬁcult to achieve high W
scores as the numbers of experts increase.21 For the
dichotomous variables, we report both the absolute
agreement and Gwet’s AC1. The absolute agreementVolume 38 Number 7
Table I. The six drug-related queries from general practitioners (GPs) were simultaneously submitted to seven
Scandinavian drug information centers (DICs) during a study period of 8 weeks.*
Query No. Query Category
I A female patient presents with deep, infected pockets close
to the jaw bone, and needs to have these rinsed every 4th to
5th week for the next 6 months. The patient uses alendronate
70 mg once weekly. Should alendronate be discontinued
during treatment?
Adverse effects;
pharmacokinetics
II A male patient with formerly performed gastric bypass needs
treatment for Helicobacter pylori infection due to symptomatic
peptic ulcer. The GP wants to start treatment with pantoprazole
40 mg once daily, metronidazole 400 mg BID, and amoxicillin
750 mg BID. Will the absorption of the drugs be reduced,
and are dosage adjustments necessary?
Pharmacokinetics
III A pregnant woman manifests with moderate depression
(MADRS score 29), and there is indication for treatment
with an antidepressant. What antidepressant is the ﬁrst choice
of drug during pregnancy?
Pregnancy
IV A GP has registered an increasing use of Ginkgo biloba in
nursing care homes and home nursing services. He (she) has
also registered that ginkgo might increase bleeding time. What
documentation exists on this topic, and what is the relevance
for concurrent use of, for example, warfarin, acetylsalicylic acid,
clopidogrel, and enoxaparin?
Herbal medicines; adverse
effects; drug interactions
V A male patient, aged 75 years, has gradually developed
impaired cognition for the last 5–6 months (MMS score of 18
at examination). He has essential hypertension treated with
atenolol 100 mg once daily and losartan/hydrochlorothiazide
100/12.5 mg once daily. His blood pressure was 130/90 mm
Hg at the latest appointment. He also uses simvastatin 40 mg
and acetylsalicylic acid 160 mg once daily. He uses paroxetine
40 mg in the morning for anxiety/depression, diazepam 5 mg as
needed and promethazine/propiomazine† 50 mg at night for
sleep. He also uses tolterodine 2.8/4 mg‡ once daily for
overactive bladder (dosage increased from 1.4/2 mg‡ 3 months
ago). The patient does not smoke. Can any of these drugs, or
drug interactions, increase the risk for impaired cognition?
Drug use in the elderly;
drug interactions; adverse
effects
VI A female patient, 13 weeks postpartum, presents with active
ulcerative colitis. She has earlier been treated with sulfasalazine
500 mg  3 (discontinued during pregnancy). Can she use
sulfasalazine while breast-feeding?
Breast-feeding
MADRS ¼ Montgomery and Asberg Depression Rating Scale; MMS ¼ Mini-Mental status.
*All GPs asked each query on the same day. Queries were originally asked in the Norwegian, Danish, and Swedish languages.
†Promethazine is marketed in Norway and Denmark, but not in Sweden. For the Swedish query, we used the drug
propiomazine. Both drugs are derivatives of phenothiazine with antihistaminic and anticholinergic effects.
‡Tolterodine is marketed as 2- and 4-mg depot capsules in Norway and Sweden, and as 1.4- and 2.8-mg depot capsules in
Denmark.
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Table II. Scores of detailed quality criteria used to assess the quality of responses to six drug-related queries posed to seven Scandinavian drug
information centers (DICs).
Criterion
No.* Quality Criterion
Internal Expert Evaluation External Expert Evaluation
Total Kendall’s W†Score, Mean (SD) n Kendall’s W† Score, Mean (SD) n Kendall’s W†
1 Overall impression of the
response
2.6 (1.0) 294 0.34 2.6 (1.0) 252 0.04 0.20
2 Relevance of the response 3.2 (0.7) 291 0.57 3.1 (0.8) 252 0.35 0.44
3 Conclusions/advice are in
accordance
with the presented
documentation
2.9 (0.8) 289 0.33 2.8 (0.8) 251 0.15 0.25
4 The extent of the response 3.1 (1.1) 293 0.07 3.2 (1.2) 252 0.17 0.11
5 Unnecessary information
in the response
3.0 (0.8) 291 0.21 3.0 (1.0) 251 0.22 0.21
6 Readability of the
response
2.8 (0.7) 294 0.23 2.7 (0.9) 251 0.22 0.21
7 Logical structure of the
response
2.8 (0.7) 293 0.31 2.8 (0.8) 252 0.17 0.23
8 Clinical usefulness of the
response
NA – NA 2.9 (0.9) 252 0.20 –
9 Would you feel safe
making a decision
concerning the case,
based on the
response?
NA – NA 2.6 (1.1) 247 0.12 –
10 Understanding of the
response
NA – NA 3.1 (0.7) 251 0.43 –
11 Staff member provided
extra value
to the response,
besides presenting
data‡
1.9 (1.0) 294 0.26 NA - NA –
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Table II. (continued).
Criterion
No.* Quality Criterion
Internal Expert Evaluation External Expert Evaluation
Total Kendall’s W†Score, Mean (SD) n Kendall’s W† Score, Mean (SD) n Kendall’s W†
12 All relevant aspects of the
case covered
2.7 (0.8) 293 0.31 NA - NA -
Internal Expert Evaluation External Expert Evaluation
Total Gwet’s
AC1§, (95% CI)
No of “Yes”
Responses, %
Gwet’s AC1§,
(95% CI)
No of “Yes”
Responses, %
Gwet’s AC1§,
(95% CI)
13 Advice on how to handle
the case was given
247 (84.0) 294 0.76 (0.63–0.88)‖ 201 (79.8) 252 0.73 (0.59–0.86)¶ 0.73 (0.61–0.86)¶
14 No incorrect statements
in response
256 (88.9) 288 0.81 (0.71–0.92)# NA - NA -
15 No statements that might
be misunderstood in
response
282 (95.9) 294 0.92 (0.86–0.97)** NA - NA -
16 No expressions or
abbreviations that
should have been
explained in response
277 (94.2) 294 0.88 (0.82–0.94)†† NA - NA -
NA ¼ not applicable.
*Criteria 1 to 3 and 5 to 12 were scored from 0 (poorest) to 4 (best); criterion 4 was scored 0 (poorest), 2, or 4 (best); and criteria 13 to 16 were scored either 0,
meaning no (poorest) or 4, meaning yes (best).
†Kendall’s coefﬁcient of concordance, for ordinal variables assessed by multiple experts (value, 0–1).
‡That is, interpreting data and evaluating literature critically.
§Gwet’s agreement coefﬁcient with ﬁrst-order chance correction, AC1 (value, 0–1).
‖Absolute agreement between experts (value, 0–1), 0.82.
¶Absolute agreement between experts, 0.81.
#Absolute agreement between experts, 0.85.
**Absolute agreement between experts, 0.93.
††Absolute agreement between experts, 0.89.
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Table III. Time consumption for seven Scandinavian drug information centers (DICs) answering six specific
drug-related queries.
Query No.
Requested Time
Frame
Time Consumption per Response (h:min)
Mean Median Minimum Maximum
Mean Response
Time (d)
I Within a week 05:16 03:35 01:35 12:36 3.8
II Within 2 days 04:29 03:44 02:00 10:39 1.4
III Within the next day 01:38 01:09 00:17 03:30 0.1
IV None 03:59 02:05 00:42 16:04 4.0
V None 04:50 04:08 02:06 12:25 4.1
VI None 06:38 02:50 00:35 24:17 1.4
All queries – 04:26 03:08 00:17 24:17 2.6
Clinical Therapeuticsvalue provides a sensible value of unity when all
experts agree; however, absolute agreement does not
adjust for agreement by chance.23
Of 42 cases, 2 were excluded from the regression
analysis due to lack of time estimates. In 2 other cases,
the time component for quality assurance was missing,
and we imputed this component based on all of the other
time components of all of the other cases. For detailed
quality scores, 26 single values were missing of 7800
possible values, representing 0.3% missing values. The
missing values represented 21 of 520 individual expert
evaluations (4%). We used the expectation-maximization
algorithm to do single imputation. The quality scores of
the internal experts were used for predicting the scores of
the missing values from the internal experts, and the
quality scores of the external experts were used for
predicting the scores of the missing values from the
external experts. Two imputed values were higher than
the permissible range, and these were set to the highest
possible value (ie, 4). For the calculations of agreement,
all imputed values were rounded off to the nearest integer
represented in the score of the actual quality criteria.
Statistical analyses were performed using SPSS
version 21 (IBM Corp., Armonk, New York), STATA
IC version 13 (StataCorp LP, College Station, Texas),
and AgreeStat 2013.3 (Advanced Analytics, LLC,
Gaithersburg, Maryland). P values o0.05 were con-
sidered statistically signiﬁcant.RESULTS
Both expert groups assessed the quality of the re-
sponses as “satisfactory” to “good.” The seven1744responses to each of the six queries were generally
professionally concordant, although some exceptions
did occur. The interpretation of the literature, assess-
ment of clinical signiﬁcance of the therapeutic prob-
lems, and management recommendations varied
between responses to the same query, as did both
the internal and external experts’ interpretation of
these issues.
Table II shows the results of the detailed quality
criteria as well as the measures of concordance
between experts. Generally, the scores given on each
of the quality criteria varied more among the external
than among the internal experts. Of the 42 responses,
27 (64%) were quality-assured using co-signatures,
and 24 (57%), by discussions with colleagues. In 16
responses (38%), both methods were used. Five
responses (12%) were not quality-assured by others,
whereas information was missing in two cases (5%).
Of the four responses with lowest quality scores, none
were quality-assured using co-signature, but three had
been discussed with colleagues.
Responses to the queries were given within a mean
of 2.5 days, with a minimum of 0 days (ie, the answer
was given on the same day) to a maximum 12 days.
For the three queries in which a response was
requested within a certain time frame, all responses
except one were delivered within the requested time.
Mean, median, and minimum and maximum time
consumptions, requested time frame and response
time for each query are shown in Table III. Four
centers spent a mean of 2 to 3 hours per query, two
centers spent a mean of 3 to 4 hours per query, and
one center spent a mean of 413 hours per query.Volume 38 Number 7
Table IV. Summarized quality scores for internal (clinical pharmacologists) and external (general
practitioners) experts reviewing responses to six drug-related queries posed to seven
Scandinavian drug information centers (DICs).*
Query No.
Internal Experts' Sum Score† External Experts' Sum Score‡
Mean (%) Minimum (%) Maximum (%) Mean (%) Minimum (%) Maximum (%)
I 37.0 (78) 33.3 (69) 40.9 (85) 26.7 (67) 21.3 (53) 33.0 (83)
II 37.0 (78) 28.2 (59) 41.2 (86) 29.9 (75) 17.2 (43) 35.2 (88)
III 38.1 (79) 35.4 (74) 40.8 (85) 32.0 (80) 27.8 (70) 36.2 (91)
IV 36.2 (75) 30.8 (64) 40.3 (84) 27.7 (69) 20.3 (51) 30.8 (77)
V 35.8 (75) 30.0 (63) 39.6 (83) 28.4 (71) 22.0 (55) 35.0 (88)
VI 38.7 (81) 35.1 (73) 40.3 (84) 32.5 (81) 27.2 (68) 36.8 (92)
All queries 37.1 (77) 28.2 (59) 41.2 (86) 29.5 (74) 17.2 (43) 36.8 (92)
*The possible range of sum score was 0 to 40 for the external experts' score and 0 to 48 for the internal experts' score. The
percentages represent the speciﬁc score in percentage of the maximum possible score in the same category.
†Criteria 2 to 7 and 11 to 16 (Table II) were included in the internal experts sum score.
‡Criteria 2 to 10 and 13 (Table II) were included in the external experts sum score.
L.A. Reppe et al.Table IV shows the results of the summarization of
the internal experts’ quality score and external
experts’ quality score, respectively. Table V shows
the results of the mixed model linear regression
analyses of time as a predictor variable for various
quality measurements. Sensitivity analysis excludingTable V. Results from mixed model linear regression an
different measures of quality of written ans
Scandinavian drug information centers (DICs)
Dependent Variable
Possib
Scor
Internal experts' common quality score† 0–28
External experts' common quality score† 0–28
Internal experts' sum score‡ 0–48
External experts' sum score§ 0–40
Internal experts' overall impression of response 0–4
External experts' overall impression of response 0–4
*Sums of quality scores were calculated using different combin
experts (clinical pharmacologists) and external experts (genera
†Criteria 2 to 7 and 13 (Table II) was included in the score.
‡Criteria 2 to 7 and 11 to 16 (Table II) was included in the sco
§Criteria 2 to 10 and 13 (Table II) was included in the score.
July 2016the center with the highest time consumption did not
change the results signiﬁcantly, except that the
external experts’ score were statistically signiﬁcantly
associated with a decreasing time consumption. The
inclusion of staff members’ experience did not change
the results (data not shown).alyses exploring whether time consumption predicts
wers to six drug-related queries posed to seven
(n ¼ 40; data from 2 cases are unavailable).*
le
e
Estimated Change in Quality Score
per Extra Hour Spent on Response,
(95% CI) P
–0.04 (–0.17 to 0.09) 0.52
–0.20 (–0.33 to –0.06) 0.004
–0.06 (–0.24 to 0.13) 0.56
–0.21 (–0.47 to 0.04) 0.10
0.01 (–0.02 to 0.04) 0.47
–0.05 (–0.08 to –0.01) 0.005
ations of 16 individual quality criteria assessed by internal
l practitioners).
re.
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Clinical TherapeuticsDISCUSSION
To our knowledge, this is the ﬁrst study to explore
the association between time consumption when
processing responses to drug-related queries to DICs,
and the quality of the responses. The results are
somewhat surprising; we found no association be-
tween time consumption and quality as assessed by
the internal experts. For the external expert quality
evaluation, however, we found that an increase in
time consumption was statistically signiﬁcantly asso-
ciated with a decrease in the assessed quality, both
when measured as the common quality score and as
the overall impression of the response. The clinical
importance of these ﬁndings, however, is probably
negligible. The external experts’ common quality
score was reduced with 0.2 per extra hour of work,
which means that working an extra 5 hours with a
response would decrease the score with 1.0 (of a
possible maximum of 28.0), a change not considered
clinically important. Certainly, these results do not
mean that the longer the time one spends processing a
query, the poorer the response. In addition, we cannot
extrapolate these results outside the time intervals
reported in this study. We postulate that during the
ﬁrst minutes or hours of work, the quality increases in
parallel with the time consumption, but at some point
additional time invested may not further improve
quality. Moreover, this ﬁnding could be of particular
relevance for the external experts. For these experts,
there was a tendency that the assessment of read-
ability, usefulness, and understanding of the response
decreased with increasing time consumption, as did
the assessment of whether they would feel safe making
a decision concerning the case. The responses with the
highest time consumption might be more extensive
and contain more details on, for example, study
results, which might make them more difﬁcult to read.
The length (number of words) of the responses certainly
increased with time consumption. Exploring the associa-
tion between the length of the responses and the assessed
quality, however, we found no trend that the length of the
responses affected the assessment of the quality of the
responses, among either internal or external experts. It
should however be remembered that our sample size was
small, and a lot of the total variance in quality scores
could not be accounted for in our analyses.
Compared with previous studies that used ﬁctitious
queries to assess the quality of the DIC services,15–19
the overall quality of the responses in the present1746study was satisfactory. All centers produced responses
to all study queries, and the mean scores were mostly
satisfactory to good. The response times, a factor
potentially important for the usefulness of such
responses,6 were generally satisfactory, and with one
exception, all queries were processed within the
requested timeframe. Adding the response time to
the multiple regression analyses for the external
experts (who were informed of this) had no effect on
the association between time consumption and the
common quality score, or the external experts’ sum
score. However, the association between time
consumption and total impression of the response
did not reach statistical signiﬁcance when adjusted for
response time (results not shown). Although the
external experts were not actual users of the
services, they may have emphasized the response
time, particularly in the assessment of the total
impression.
Former studies of the US DICs, although quite old,
have assessed the correctness of responses.17–19 We
did not assess the detailed correctness of the re-
sponses, as the queries were complex and had no
clear-cut answers. We chose this approach because
queries demanding simple statements of facts are not
representative of those normally posed to the DICs in
Scandinavian countries. Therefore, we also did not
produce a “correct” control response. We did ask the
internal experts whether they identiﬁed incorrect
statements in the responses, and such statements were
reported in 32 of 288 ratings (11%). Different
experts, however, actually disagreed on a few state-
ments in terms of correctness. For example, the
clinical relevance of a pharmacokinetic drug interac-
tion between paroxetine and atenolol was deemed to
be clinically signiﬁcant by some experts, who re-
warded the responses that made this interpretation,
whereas others assessed this drug interaction to be
clinically nonsigniﬁcant, discrediting these responses.
This example reﬂects how challenging it is both to
respond to these queries and to assess the responses. It
is also complicated to make objective quality criteria
for DICs’ responses to complex queries, as the assess-
ment of quality is clearly individual and dependent on
the experts’ knowledge, experience, and attitudes.
By comparing different responses to the same
queries, we would theoretically be able to determine
which elements increase or decrease the quality of
responses. The responses with the lowest quality wereVolume 38 Number 7
L.A. Reppe et al.quite easy to identify, whereas high-quality responses
were more difﬁcult to point out, as the differences
between scores of individual responses were small.
Comparing high-quality to low-quality responses, the
quality criteria with the largest difference in numeric
score was whether advice was given, and the degree to
which advice was given certainly varied between
responses. The differences were also large in terms
of whether external experts would feel safe making a
decision concerning the cases.
Of the four responses that, based on summarized
scores from both the internal and external experts,
had the lowest quality, none were quality-assured
using co-signature, but three were discussed with
colleagues. Although the number of responses is small,
this small number may suggest that the use of co-
signatures is a preferable way of quality-assuring the
written responses. The use of co-signature implies that
another colleague has read the original query and the
suggested written response and discussed these with
the staff member primarily involved in the query. The
results also imply that oral discussions with colleagues
may not always be sufﬁcient for quality assurance,
which is especially true for the centers that primarily
give written responses; putting your signature on a
paper might to a larger extent involve an obligation or
a commitment.
The agreement within both internal and external
experts was generally low in this study. This ﬁnding is
not surprising, as the assessment of quality of drug
information responses is very subjective.8,24 Looking
at the results of the dichotomous variables, there was
a higher level of agreement. For future studies, how-
ever, adding a more formal qualitative approach may
be a valuable supplement as it allows for more
thorough follow-up of experts’ assessments and
comments.
Time consumption when answering the study
queries varied considerably, as did the time consump-
tion in responding to “real” queries, reported in our
previous study.20 The mean response time was higher
for these study queries than for the real queries
processed during the same time period (266 and 178
minutes, respectively). The reasons for this difference
might be that the center with the clearly highest time
consumption had a greater proportion of the
responses in the present study. Also, a large
proportion of the study queries (22 [52%]) was
handled by staff members with 0 to 2 years ofJuly 2016experience in the present study, a factor shown to
predict an increase in time consumption.20
Study Strengths and Limitations
We used an experimental, prospective design as
suggested by Spinewine et al,13 giving us extensive
control over the collected data. We ascertained that
the collected responses were the ones that were
actually given to the enquirers, and the staff
members were blinded in terms of which queries
were study queries. We have no conﬁrmative
knowledge that the blinding was violated. We
cannot exclude that staff members have worked in a
way different from usual during the study period to
increase the quality of the responses, and that this
factor may have increased the time consumption.
However, we consider the duration of the study
period (8 weeks) being a strength, as we believe the
staff members got used to both the estimation of time
consumption and the thought of being evaluated,
which may have decreased the suspiciousness toward
queries as the study period went on.
In addition to different DICs’ styles and staff
members’ experiences,20 one possible explanation for
the great variation in time consumption is the staff
members’ former knowledge of the speciﬁc topics.
Some staff members may have spent a short time
giving a good-quality response because they were
familiar with the documentation. We were unable to
control for this factor, as we have no registration of
each staff member’s personal knowledge within the
area. Another inaccuracy of the multivariate analyses
is that we did not control for the fact that some staff
members answered more than one query.
External reviewers like our GPs might help reduce
bias13 and are particularly suitable for written
responses.9 Our external experts were recruited via
the leaders of the centers and were familiar with the
services. As such, we do not know whether they were
completely unbiased, especially toward their own
center. The same argument is valid also for the
internal experts, who were clinical pharmacologists
recruited from ﬁve of the participating DICs. We did
not adjust for this factor in the multivariate analyses.
However, all experts were blinded at least to the
responses from the four DICs in Norway.
The two expert groups were intended to review the
quality of responses from different angles: The inter-
nal experts had special competence in the ﬁeld of1747
Clinical Therapeuticsclinical pharmacology and should be suitable for
assessing the correctness and completeness from a
scientiﬁc point of view. The external experts repre-
sented the users of the centers and should be suitable
for assessing, for example, the usefulness of the
responses. In retrospect, the members of the two
groups of experts may have been more similar in their
focus than expected. Our external experts may not
have been representative of all GPs, as several of them
had a PhD and were working part-time in academia.
Still, there are differences in the results between
these two groups that may reﬂect their different
perspectives.
We have used the word quality in its broadest
sense, as the “standard of something, measured
against other thing of a similar kind.”25 The use of
explicit criteria has been discussed by others.24 One
might argue that the most important quality criterion
is what actually happens to the patients of health care
professionals posing queries to DICs.2 However, due
to the lack of controls and because one response could
affect several future patients, it is a challenge to
measure the impact of these services in such a
perspective. Our quality criteria were based on data
from earlier studies of quality assessments of DIC
responses,2,10,15–19 as well as our own knowledge of
the services. Our choice of criteria has not been
validated, but as pointed out, there is also a lack of
widely accepted criteria.1,13,24 We do not know how
the individual experts interpreted the assessment
criteria, and clearly, different experts may have em-
phasized different aspects of the responses. In retro-
spect, however, we observed that the quality criterion
“overall impression of the response” might be just as
suitable for measuring the overall quality as any of the
summarized scores.CONCLUSIONS
The quality of responses processed by the DICs in
Scandinavian countries was generally satisfactory to
good. We found large variances in both style and
content, as well as in the time consumed to process
them. We found no indication that increasing time
consumption also increased the quality of the re-
sponses; however, differences in quality were small,
and the ﬁndings should be interpreted with caution.
Other factors that may be more or less associated with
an increasing time consumption may be more1748important for quality (eg, the digestion of documen-
tation, giving speciﬁc advice when possible, and the
use of co-signatures for quality assurance).ACKNOWLEDGMENTS
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